| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 特色原料药及中间体(元) | 523,212,213.61 | - | 731,532,152.21 | - | 693,095,401.74 |
| 新药定制研发和生产服务(CDMO)(元) | 2,291,374,984.78 | - | 1,970,659,480.91 | - | 2,482,354,923.59 |
| 贸易类及其他(元) | 56,360,134.83 | 56,088,226.03 | 62,088,187.19 | 65,288,585.50 | 79,192,196.76 |
| 非甾体抗炎药物(元) | - | 276,653,770.94 | - | 303,668,616.87 | - |
| 合同定制(元) | - | 3,870,554,542.49 | - | 4,079,438,603.45 | - |
| 降血糖类药(元) | - | 189,727,475.08 | - | 160,187,056.89 | - |
| 抗感染类药物(元) | - | 304,413,153.40 | - | 332,778,980.57 | - |
| 中枢神经类药物(元) | - | 388,906,029.31 | - | 464,471,895.27 | - |
| 营业成本(元) | |||||
| 特色原料药及中间体(元) | 401,491,691.48 | - | 576,545,264.56 | - | 470,499,222.55 |
| 新药定制研发和生产服务(CDMO)(元) | 1,351,447,049.19 | - | 1,161,589,442.50 | - | 1,465,693,820.50 |
| 贸易类及其他(元) | 42,839,774.71 | 46,037,603.70 | 52,772,413.07 | 53,859,114.60 | 68,573,845.18 |
| 非甾体抗炎药物(元) | - | 171,679,207.86 | - | 168,076,810.85 | - |
| 合同定制(元) | - | 2,385,038,893.10 | - | 2,433,952,057.31 | - |
| 降血糖类药(元) | - | 182,347,389.23 | - | 136,862,862.61 | - |
| 抗感染类药物(元) | - | 321,899,600.24 | - | 280,340,363.04 | - |
| 中枢神经类药物(元) | - | 250,547,699.94 | - | 260,674,101.35 | - |
| 毛利(元) | |||||
| 特色原料药及中间体(元) | 121,720,522.13 | - | 154,986,887.65 | - | 222,596,179.19 |
| 新药定制研发和生产服务(CDMO)(元) | 939,927,935.59 | - | 809,070,038.41 | - | 1,016,661,103.09 |
| 贸易类及其他(元) | 13,520,360.12 | 10,050,622.33 | 9,315,774.12 | 11,429,470.90 | 10,618,351.58 |
| 非甾体抗炎药物(元) | - | 104,974,563.08 | - | 135,591,806.02 | - |
| 合同定制(元) | - | 1,485,515,649.39 | - | 1,645,486,546.14 | - |
| 降血糖类药(元) | - | 7,380,085.85 | - | 23,324,194.28 | - |
| 抗感染类药物(元) | - | -17,486,446.84 | - | 52,438,617.53 | - |
| 中枢神经类药物(元) | - | 138,358,329.37 | - | 203,797,793.92 | - |
| 毛利率(%) | |||||
| 特色原料药及中间体(%) | 23.26 | - | 21.19 | - | 32.12 |
| 新药定制研发和生产服务(CDMO)(%) | 41.02 | - | 41.06 | - | 40.96 |
| 贸易类及其他(%) | 23.99 | 17.92 | 15.00 | 17.51 | 13.41 |
| 非甾体抗炎药物(%) | - | 37.94 | - | 44.65 | - |
| 合同定制(%) | - | 38.38 | - | 40.34 | - |
| 降血糖类药(%) | - | 3.89 | - | 14.56 | - |
| 抗感染类药物(%) | - | -5.74 | - | 15.76 | - |
| 中枢神经类药物(%) | - | 35.58 | - | 43.88 | - |
| 收入构成(%) | |||||
| 特色原料药及中间体(%) | 18.22 | - | 26.46 | - | 21.30 |
| 新药定制研发和生产服务(CDMO)(%) | 79.81 | - | 71.29 | - | 76.27 |
| 贸易类及其他(%) | 1.96 | 1.10 | 2.25 | 1.21 | 2.43 |
| 非甾体抗炎药物(%) | - | 5.44 | - | 5.62 | - |
| 合同定制(%) | - | 76.10 | - | 75.46 | - |
| 降血糖类药(%) | - | 3.73 | - | 2.96 | - |
| 抗感染类药物(%) | - | 5.98 | - | 6.16 | - |
| 中枢神经类药物(%) | - | 7.65 | - | 8.59 | - |
| 毛利构成(%) | |||||
| 特色原料药及中间体(%) | 11.32 | - | 15.92 | - | 17.81 |
| 新药定制研发和生产服务(CDMO)(%) | 87.42 | - | 83.12 | - | 81.34 |
| 贸易类及其他(%) | 1.26 | 0.58 | 0.96 | 0.55 | 0.85 |
| 非甾体抗炎药物(%) | - | 6.07 | - | 6.54 | - |
| 合同定制(%) | - | 85.93 | - | 79.41 | - |
| 降血糖类药(%) | - | 0.43 | - | 1.13 | - |
| 抗感染类药物(%) | - | -1.01 | - | 2.53 | - |
| 中枢神经类药物(%) | - | 8.00 | - | 9.84 | - |